Amikar Sehdev1, Ya-Chen T Shih2, Dezheng Huo3, Benjamin Vekhter4, Christopher Lyttle4, Blase Polite5. 1. Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, U.S.A. amikar.sehdev@uchospitals.edu. 2. Section of Hospital Medicine, Department of Medicine, University of Chicago, Chicago, IL, U.S.A. 3. Department of Health Studies, University of Chicago, Chicago, IL, U.S.A. 4. The Center for Health and the Social Sciences, University of Chicago, Chicago, IL, U.S.A. 5. Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, U.S.A.
Abstract
BACKGROUND: There is conflicting evidence for the role of statins in the primary prevention of colorectal cancer (CRC). We conducted a case control study (N=357,702) in the non-elderly adult US population (age=18-64 years) with the primary objective to examine the association between CRC and statin use. PATIENTS AND METHODS: MarketScan® databases were used to identify patients with CRC. A case was defined as having an incident diagnosis of CRC. Up to ten individually matched controls (age, sex, region and date of diagnosis) were selected per case. Statin exposure was assessed by prescription tracking in the 12 months prior to the index date. Conditional logistic regression was used to adjust for multiple potential confounders and calculate adjusted odds ratios (AOR). RESULTS: The mean age of participants was 54 years; 52% males and 48% females. In a multivariable model, any statin use was associated with 26% reduced odds of CRC (AOR, 0.74, 95% confidence interval (CI), 0.72-0.77, p<0.001). Age-stratified analyses showed a stronger effect of statins on CRC in participants aged 55 years or younger (AOR, 0.67, 95% CI, 0.63-0.71, p<0.001) than in participants aged above 55 years (AOR, 0.79, 95% CI, 0.76-0.82, p<0.001); the age-by-statin interaction was statistically significant (p<0.001). The dose-response analyses performed with simvastatin only showed a trend towards significance between the duration of simvastatin exposure and odds of developing CRC (p=0.06). CONCLUSIONS: Statins appears to reduce the risk of CRC in non-elderly US population. Chemoprevention with statin might be more effective in non-elderly US population. Copyright
BACKGROUND: There is conflicting evidence for the role of statins in the primary prevention of colorectal cancer (CRC). We conducted a case control study (N=357,702) in the non-elderly adult US population (age=18-64 years) with the primary objective to examine the association between CRC and statin use. PATIENTS AND METHODS: MarketScan® databases were used to identify patients with CRC. A case was defined as having an incident diagnosis of CRC. Up to ten individually matched controls (age, sex, region and date of diagnosis) were selected per case. Statin exposure was assessed by prescription tracking in the 12 months prior to the index date. Conditional logistic regression was used to adjust for multiple potential confounders and calculate adjusted odds ratios (AOR). RESULTS: The mean age of participants was 54 years; 52% males and 48% females. In a multivariable model, any statin use was associated with 26% reduced odds of CRC (AOR, 0.74, 95% confidence interval (CI), 0.72-0.77, p<0.001). Age-stratified analyses showed a stronger effect of statins on CRC in participants aged 55 years or younger (AOR, 0.67, 95% CI, 0.63-0.71, p<0.001) than in participants aged above 55 years (AOR, 0.79, 95% CI, 0.76-0.82, p<0.001); the age-by-statin interaction was statistically significant (p<0.001). The dose-response analyses performed with simvastatin only showed a trend towards significance between the duration of simvastatin exposure and odds of developing CRC (p=0.06). CONCLUSIONS: Statins appears to reduce the risk of CRC in non-elderly US population. Chemoprevention with statin might be more effective in non-elderly US population. Copyright
Authors: Amikar Sehdev; Ya-Chen T Shih; Benjamin Vekhter; Marc B Bissonnette; Olufunmilayo I Olopade; Blase N Polite Journal: Cancer Date: 2014-11-25 Impact factor: 6.860
Authors: Yin Zhang; Kana Wu; Andrew T Chan; Jeffrey A Meyerhardt; Edward L Giovannucci Journal: Am J Gastroenterol Date: 2022-01-01 Impact factor: 12.045
Authors: Antonio Rodríguez-Miguel; Encarnación Fernández-Antón; Diana Barreira-Hernández; Luis A García-Rodríguez; Miguel Gil; Alberto García-Lledó; Francisco J De Abajo Journal: J Clin Med Date: 2022-03-10 Impact factor: 4.241